Senseonics Holdings Inc (SENS)
NASDAQ:SENS
Want to see SENS full AI Analyst Report?
Top Page
Senseonics Holdings
(NASDAQ:SENS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$5.00
▼(-26.14% Downside)
Action:ReiteratedDate:05/05/26
The score is held down primarily by weak financial performance (large recurring losses and sustained cash burn) and bearish technicals. Offsetting factors include constructive earnings-call guidance on accelerating revenue and improving gross margin, plus liquidity support from recent financing and European operational expansion; however, the planned 2026 expense ramp and cash utilization keep overall risk elevated.
Positive Factors
Strong U.S. patient and prescriber growth
Sustained, large-scale patient and prescriber adoption is a durable indicator of product-market fit. Doubling the U.S. patient base and >80% prescriber growth supports recurring sensor consumable sales, improves lifetime value per patient, and creates a foundation for multi-quarter revenue scaling independent of short-term trends.
Negative Factors
Persistent negative operating and free cash flow
Chronic negative operating and free cash flows force ongoing reliance on external financing. Over 2–6 months, this raises dilution and leverage risk if revenue and margin gains do not sufficiently outpace planned cash use, and it constrains strategic optionality if capital markets tighten or execution slips.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong U.S. patient and prescriber growth
Sustained, large-scale patient and prescriber adoption is a durable indicator of product-market fit. Doubling the U.S. patient base and >80% prescriber growth supports recurring sensor consumable sales, improves lifetime value per patient, and creates a foundation for multi-quarter revenue scaling independent of short-term trends.
Read all positive factors
Senseonics Holdings (SENS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$249.51M
Dividend YieldN/A
Average Volume (3M)376.43K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth56.89%
EPS Growth34.00%
CountryUS
Employees117
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.85
Shares Outstanding49,802,963
10 Day Avg. Volume297,791
30 Day Avg. Volume376,432
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.77
Price to Sales (P/S)6.53
P/FCF Ratio-3.82
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue5.68
Enterprise Value/Gross Profit12.64
Enterprise Value/Ebitda-3.92
Forecast
1Y Price Target
$18.92Price Target Upside179.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$60.11M
Senseonics Holdings Business Overview & Revenue Model
Company Description
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eve...
How the Company Makes Money
Senseonics primarily makes money by selling its Eversense CGM systems and related supplies and services through commercialization partnerships. Revenue is generated from sales of implantable glucose sensors, external transmitters, and other system...
Senseonics Holdings Earnings Call Summary
Earnings Call Date:Mar 02, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call communicates strong commercial momentum and significant operational progress: robust revenue growth (full-year +~57% to $35.3M), doubling of the U.S. patient base, major margin expansion to >50%, CE marking and a strategic pump integration, and an aggressive 2026 revenue guide (+65% to +76%). These positives are tempered by deliberate, large near-term investments—notably a planned $150M–$160M operating cost base in 2026, $110M–$120M projected cash burn, higher SG&A and transitional commission costs—which will keep the company unprofitable near term and create execution and timing risks (especially in Europe and due to seasonality). Overall, the call framed 2025 as a transformation year with an operational playbook in place to scale in 2026; upside exists if patient retention, DTC efficiency and additional pump partnerships accelerate adoption, while the main risks are the heavy short-term cash and expense commitments required to capture that growth.Positive Updates
Strong Revenue Growth
Full-year 2025 revenue of $35.3M versus $22.5M in 2024 (approx. +57% year-over-year); Q4 2025 net revenue grew 72% to $14.3M (Q4 2024: $8.3M). U.S. revenue grew to $27.9M in 2025 (from $15.3M prior year, ~+82%).
Negative Updates
Large Increase in Operating Expenses Expected
Company expects 2026 operating expenses of $150M to $160M (an increase of about $70M consistent with prior Ascensia commercial spend) as sales & marketing and the commercial organization are integrated; operating leverage expected to improve over time but 2026 is a heavy investment year.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Full-year 2025 revenue of $35.3M versus $22.5M in 2024 (approx. +57% year-over-year); Q4 2025 net revenue grew 72% to $14.3M (Q4 2024: $8.3M). U.S. revenue grew to $27.9M in 2025 (from $15.3M prior year, ~+82%).
Read all positive updates
Company Guidance
Senseonics guided 2026 global net revenue of roughly $58–62 million (up ~65–76% versus 2025’s $35.3M), with revenue weighted to the back half of the year (~40% 1H / ~60% 2H) and Europe expected to be ~20% of revenue after a Q2 rollout; management also expects to recognize 100% of revenues going forward. They forecast full‑year gross profit margin >50% (rising sequentially), total operating expenses of $150–160M (≈$70M higher to support the in‑house commercial organization), and cash utilization of $110–120M in 2026; as of 12/31/2025 cash was $94.3M and debt/accrued interest $35.3M (Hercules facility expanded to $100M with ~$65M incremental availability). Key commercial investments include DTC spend of ~$12–15M, expanding the EON inserter network from ~60 to ~100 providers (targeting ~30–35% of U.S. insertions), and an ambition to double the U.S. patient base again in 2026 after 2025’s 103% new patient starts and >80% growth in active prescribers.Senseonics Holdings Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
41
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 35.26M | 22.47M | 22.39M | 16.39M | 13.68M |
| Gross Profit | 15.76M | 533.00K | 3.09M | 2.73M | -811.00K |
| EBITDA | -64.07M | -68.70M | -48.01M | 161.81M | -284.51M |
| Net Income | -69.11M | -78.62M | -60.39M | 142.12M | -302.47M |
Balance Sheet | |||||
| Total Assets | 126.27M | 100.44M | 138.22M | 177.67M | 198.93M |
| Cash, Cash Equivalents and Short-Term Investments | 94.03M | 74.60M | 109.46M | 144.01M | 129.91M |
| Total Debt | 41.37M | 61.05M | 47.78M | 75.38M | 64.21M |
| Total Liabilities | 65.22M | 116.99M | 64.77M | 180.25M | 384.46M |
| Stockholders Equity | 61.05M | -16.55M | 73.45M | -2.58M | -185.53M |
Cash Flow | |||||
| Free Cash Flow | -60.24M | -62.70M | -70.51M | -66.62M | -56.29M |
| Operating Cash Flow | -59.13M | -60.47M | -70.16M | -66.31M | -56.08M |
| Investing Cash Flow | -53.42M | 32.84M | 89.71M | 26.88M | -148.75M |
| Financing Cash Flow | 78.19M | 26.83M | 20.37M | 41.76M | 220.08M |
Senseonics Holdings Technical Analysis
Neutral
6.77
Price Trends
6.98
Negative
6.79
Negative
7.82
Negative
Market Momentum
<0.01
Negative
51.37
Neutral
61.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Neutral. The current price of 6.77 is above the 20-day moving average (MA) of 6.67, below the 50-day MA of 6.98, and below the 200-day MA of 7.82, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.37 is Neutral, neither overbought nor oversold. The STOCH value of 61.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SENS.
Senseonics Holdings Risk Analysis
Senseonics Holdings disclosed 69 risk factors in its most recent earnings report. Senseonics Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Senseonics Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $23.17B | 30.31 | 33.83% | ― | 16.15% | 76.15% | |
69 Neutral | $11.87B | 49.21 | 17.36% | ― | 30.73% | -41.15% | |
68 Neutral | $3.23B | 27.15 | -21.49% | ― | 11.08% | -485.09% | |
60 Neutral | $78.44M | 480.81 | 10.27% | ― | 14.21% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $249.51M | -2.77 | -104.17% | ― | 56.89% | 34.00% | |
45 Neutral | $1.36B | -634.53 | -141.98% | ― | 7.93% | -108.60% |
* Healthcare Sector Average
SENS
Senseonics Holdings
5.01
-8.19
-62.05%
DXCM
Dexcom
60.04
-21.49
-26.36%
PODD
Insulet
171.39
-87.48
-33.79%
TNDM
Tandem Diabetes Care
19.87
-1.45
-6.80%
LIVN
LivaNova
59.07
23.91
68.00%
XTNT
Xtant Medical Holdings
0.56
0.05
10.24%
Senseonics Holdings Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Senseonics Expands Senior Term Loan Facility to 2029
Positive
May 4, 2026
On May 1, 2026, Senseonics Holdings, Inc. and its subsidiaries entered into a Second Amendment to their Loan and Security Agreement, expanding access to up to $140 million in senior secured term loans maturing on September 3, 2029. The facility in...
Business Operations and StrategyPrivate Placements and Financing
Senseonics Holdings Boosts Capital via Equity and Loan Expansion
Positive
May 1, 2026
On April 30, 2026, Senseonics Holdings, Inc. agreed to sell 8 million shares of common stock and 8 million pre‑funded warrants in an underwritten public offering priced at $5.00 per share, with underwriters holding a 30‑day option to b...
Business Operations and StrategyM&A Transactions
Senseonics Expands European Eversense Operations via Asset Agreements
Positive
Mar 12, 2026
On December 31, 2025, Senseonics entered into a master asset purchase agreement with Ascensia Diabetes Care to acquire assets related to the marketing, sale and distribution of the Eversense CGM product in the U.S., effective January 1, 2026, and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.